Gender and hospitalization patterns among HIV-Infected drug users before and after the availability of highly active antiretroviral therapy

被引:52
|
作者
Floris-Moore, M
Lo, YT
Klein, RS
Budner, N
Gourevitch, MN
Moskaleva, G
Schoenbaum, EE
机构
[1] Montefiore Med Ctr, AIDS Res Program, Bronx, NY 10467 USA
[2] Montefiore Med Ctr, Div Infect Dis, Dept Med, Bronx, NY 10467 USA
[3] Montefiore Med Ctr, Dept Epidemiol & Populat Sci, Bronx, NY 10467 USA
[4] Montefiore Med Ctr, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA
[5] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA
[6] Albert Einstein Coll Med, Bronx, NY 10467 USA
关键词
HIV; AIDS; highly active antiretroviral therapy; hospitalization; gender differences;
D O I
10.1097/00126334-200311010-00012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We examined highly active antiretroviral therapy (HAART) era and pre-HAART era hospitalization rates among 604 HIV-infected drug users in a prospective study in Bronx, New York. Medical history and risk behaviors were elicited by semiannual interviews. Standardized medical record review abstracted discharge diagnoses for all hospitalizations. Hospitalization rates from January 1997 to December 2000 were compared with rates from January 1992 to December 1996. The rate of hospitalizations per 100 patient-years in the HAART era was 49.3 compared with 44.1 in the pre-HAART era (P = 0.13). Among women, the rate was significantly higher in the HAART era than in the pre-HAART era (68.1 vs. 49.4 hospitalizations per 100 patient-years, respectively; P = 0.01). In the second era, HAART users had lower rates than those who did not use HAART (37.2 vs. 83.4 hospitalizations per 100 patient-years, respectively; P < 0.001) for both HIV-associated and non-HIV-associated illnesses. Multivariate analysis revealed that in the HAART era, female gender (relative risk ratio = 1.72, P = 0.03) and not using HAART (relative risk ratio = 1.82, P = 0.02) independently predicted increased hospitalization risk. In the pre-HAART era, women were at independently higher risk of hospitalization (relative risk ratio = 1.36, P = 0.05). Among HIV-infected drug users, those who use HAART have a decreased risk of hospitalization; those who do not use HAART remain at high risk of continuing morbidity from both HIVrelated and non-HIV-related illness and have high hospitalization rates.
引用
收藏
页码:331 / 337
页数:7
相关论文
共 50 条
  • [1] Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy
    Puthanakit, Thanyawee
    Aurpibul, Linda
    Oberdorfer, Peninnah
    Akarathum, Noppadon
    Kanjananit, Suparat
    Wannarit, Pornphun
    Sirisanthana, Thira
    Sirisanthana, Virat
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (04) : 599 - 604
  • [2] Highly active antiretroviral therapy and survival in HIV-Infected injection drug users
    Wood, Evan
    Hogg, Robert S.
    Lima, Viviane Dias
    Kerr, Thomas
    Yip, Benita
    Marshall, Brandon D. L.
    Montaner, Julio S. G.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (05): : 550 - 554
  • [3] Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy
    Semba, RD
    Shah, N
    Vlahov, D
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (04): : 315 - 319
  • [4] Staging for antiretroviral therapy among HIV-infected drug users
    Wood, E
    Hogg, RS
    Bonner, S
    Kerr, T
    Li, K
    Palepu, A
    Guillemi, S
    Schechter, MT
    Montaner, JSG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (10): : 1175 - 1177
  • [5] HIV-related wasting in HIV-infected drug users in the era of highly active antiretroviral therapy
    Campa, A
    Yang, ZF
    Lai, SH
    Xue, LH
    Phillips, JC
    Sales, S
    Page, JB
    Baum, MK
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (08) : 1179 - 1185
  • [6] Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy
    Bouhnik, AD
    Préau, M
    Vincent, E
    Carrieri, MP
    Gallais, H
    Lepeu, G
    Gastaut, JA
    Moatti, JP
    Spire, B
    [J]. ANTIVIRAL THERAPY, 2005, 10 (01) : 53 - 61
  • [7] Effect of Highly Active Antiretroviral Therapy on Hospitalization Characteristics of HIV-Infected Patients
    R. Nuesch
    N. Geigy
    E. Schaedler
    M. Battegay
    [J]. European Journal of Clinical Microbiology and Infectious Diseases , 2002, 21 : 684 - 687
  • [8] Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-infected patients
    Nuesch, R
    Geigy, N
    Schaedler, E
    Battegay, M
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (09) : 684 - 687
  • [9] Time to initiating highly active antiretroviral therapy among HIV infected injection drug users
    Celentano, DD
    Galai, N
    Sethi, AK
    Shah, NG
    Strathdee, SA
    Vlahov, D
    Gallant, JE
    [J]. AIDS, 2001, 15 (13) : 1707 - 1715
  • [10] Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy
    Markert, ML
    Alvarez-McLeod, AP
    Sempowski, GD
    Hale, LP
    Horvatinovich, JM
    Weinhold, KJ
    Bartlett, JA
    D'Amico, TA
    Haynes, BF
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (17) : 1635 - 1643